No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3767-3772

  Midtvedt, Karsten ^a   Jenssen, Trond ^a,b   Hartmann, Anders ^a   Vethe, Nils Tore ^a   Bergan, Stein ^a   Havnes, Kjerstin ^a   Sberg, Anders ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

insulin secretion and sensitivity; once daily tacrolimus; renal transplantation

Indexed keywords

AZATHIOPRINE; C PEPTIDE; GLUCOSE; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GRAFT RECIPIENT; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 80155172648     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr153     Document Type: Article

References (32)

1. Montori VM, Basu A, Erwin PJ et al. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 2002; 25: 583-592
2. Cosio FG, Pesavento TE, Kim S et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440-1446
3. Hjelmesaeth J, Hartmann A, Leivestad T et al. The impact of earlydiagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-595
4. Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185
5. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16: 496-506
6. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814
7. Heisel O, Heisel R, Balshaw R et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583-595
8. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials. BMJ 1999; 318: 1104-1107
9. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514
10. Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885
11. Boots JM, van Duijnhoven EM, Christiaans MH et al. Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221-227
12. Ishibashi M, Yoshida K, Ozono S et al. Experimental study of tacrolimus immunosuppression on the mode of administration: Efficacy of constant intravenous infusion avoiding C(max). Transplant Proc 2001; 33: 559-560
13. van Hooff JP, Alloway RR, Trunecka P et al. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant 2011; 25: E1-12
14. Alloway R, Steinberg S, Khalil K et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extendedrelease formulation in stable kidney transplant recipients. Transplantation 2007; 83: 1648-1651
15. Florman S, Alloway R, Kalayoglu M et al. Once-daily tacrolimus extended release formulation: Experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007; 83: 1639-1642
16. Silva HT Jr, Yang HC, Abouljoud M et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/ MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595-608
17. Wlodarczyk Z, Squifflet JP, Ostrowski M et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: A randomized, open-label trial. Am J Transplant 2009; 9: 2505-2513
18. Kramer BK, Charpentier B, Backman L et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: A randomized phase III study. Am J Transplant 2010; 10: 2632-2643
19. Mitrakou A, Vuorinen-Markkola H, Raptis G et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. J Clin Endocrinol Metab 1992; 75: 379-382
20. Nankivell BJ, Gruenewald SM, Allen RD et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-1689
21. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098
22. Ekstrand AV, Eriksson JG, Gronhagen-Riska C et al. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation 1992; 53: 563-569
23. Nam JH, Mun JI, Kim SI et al. beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71: 1417-1423
24. Duijnhoven EM, Boots JM, Christiaans MH et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 2001; 12: 583-588
25. Ghisdal L, Bouchta NB, Broeders N et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: A single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008; 21: 146-151
26. Radu RG, Fujimoto S, Mukai E et al. Tacrolimus suppresses glucoseinduced insulin release from pancreatic islets by reducing glucokinase activity. Am J Physiol Endocrinol Metab 2005; 288: E365-E371
27. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396-402
28. Hirano Y, Fujihira S, Ohara K et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992; 53: 889-894
29. Filler G, Neuschulz I, Vollmer I et al. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000; 15: 867-871
30. de Jonge H, Kuypers DR, Verbeke K et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523-529
31. Crespo M, Mir M, Marin M et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009; 41: 2115-2117
32. Hougardy JM, Broeders N, Kianda M et al. Conversion from prograf to advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011; 91: 566-569